SYRS - Syros Pharmaceuticals, Inc.
IEX Last Trade
0.2065
-1.794 -868.523%
Share volume: 0
Last Updated: Tue 24 Dec 2024 05:59:58 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$2.00
-1.79
-89.68%
Fundamental analysis
31%
Profitability
25%
Dept financing
22%
Liquidity
66%
Performance
31%
Performance
5 Days
1.45%
1 Month
-21.11%
3 Months
-89.43%
6 Months
-96.50%
1 Year
-97.11%
2 Year
-93.50%
Key data
Stock price
$0.21
DAY RANGE
$0.20 - $2.00
52 WEEK RANGE
$0.21 - $8.17
52 WEEK CHANGE
-$97.22
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
Company detail
CEO: Nancy A. Simonian
Region: US
Website: syros.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: syros.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Syros Pharmaceuticals, Inc. focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome.
Recent news